Manufacturing
Process Development and ManufacturingRepertoire’s proprietary process development and manufacturing capabilities enable us to create the Right Medicine for the Right Patient at Right Dose and Potency – and do it at scale. Our optimized manufacturing yields younger, non-exhausted T cells, high numbers of reactive T cells, and multiple T cell clones targeting multiple antigens. Each production run generates a sufficient supply of drug product for multiple dosing of the patient.
We began our first trial in 2019 with a pan-tumor antigen repertoire found in numerous solid tumor types using our first-generation manufacturing process. We have recently introduced a second-generation manufacturing process, which has substantially increased the number of reactive T cells and number of younger phenotypes.
Our process development and manufacturing infrastructure are in place today.
Properties | Repertoire Immune Medicines | Others (e.g., CAR-T) |
---|---|---|
Requires Genetic Engineering | No | Yes |
Cytokines Attached to T Cell | Yes | No |
# of Clones | Multiple | 1 |
Doses/Manufacturing Run | Multiple | 1 |
Scalability | Cost-Efficient | Expensive |
With our suite of technologies, we have the ability to design and develop targeted immune medicines.
View Pipeline